Clinical Trial

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March…

11 months ago

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and…

11 months ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial

MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,…

11 months ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose…

11 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first…

11 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first…

11 months ago

Americord Releases Cord Blood Stem Cells for Treatment of Motor Neuron Disease

SOMERSET, NJ / ACCESSWIRE / February 23, 2024 / Americord, a leading private stem cell bank, announced the release of…

11 months ago

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of…

11 months ago

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided…

11 months ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…

11 months ago